Zdrowie i gospodarka · 24.02.2022
Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" (the Program) and an opportunity for public comment. The topics to be discussed are the final assessment and public stakeholder views of the Program.